MELK Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji B lymphocyte cell line, providing a powerful loss-of-function model for dissecting the role of maternal embryonic leucine zipper kinase (MELK) in human cancer biology. This product is engineered through CRISPR/Cas9-mediated disruption of the MELK gene, resulting in a heterogeneous pool of cells with abrogated kinase activity, enabling researchers to interrogate MELK-dependent signaling networks, cell cycle regulatory mechanisms, and apoptotic pathways without the clonal artifacts associated with monoclonal isolates. As a polyclonal population, it more accurately reflects the genetic and phenotypic diversity inherent in tumor cell populations, making it suitable for robust functional genomic screens and pharmacological studies where uniform knockout efficiency is not required across all cells.
The parental Raji cell line is an Epstein?CBarr virus (EBV)-positive, lymphoblastoid cell line originally established from a patient with Burkitt lymphoma. Raji cells grow in suspension, exhibit mature B lymphocyte characteristics including robust antibody production and antigen presentation capacity, and serve as a well-established model for studying adaptive immunity and B-cell malignancies. Their lymphoblastoid phenotype and continuous proliferation in culture allow reproducible large-scale experiments, while the EBV-driven background recapitulates key aspects of viral oncogenesis, providing a physiologically relevant context for investigating tumor cell dependencies on host serine/threonine kinases.
MELK functions as an oncogenic serine/threonine kinase critically involved in cell cycle progression, mitotic entry, and stem cell self-renewal. It is activated by upstream regulators such as TP53, FOXM1, E2F1, and growth factor signaling, and propagates its effects by phosphorylating downstream targets including CDC25B and BCL2L12. This kinase directly promotes G2/M transition and suppresses apoptosis, thereby facilitating uncontrolled proliferation and tumor survival. MELK integrates signals from multiple pathways??mTOR, MAPK, p53, and Wnt??and forms complexes with AP-1 transcription factors, Smad proteins, and various cell cycle regulators, positioning it as a central node linking proliferative and anti-apoptotic networks. Its transcriptional activation by FOXM1 and repression by TP53 underscore its role in balancing growth and cell death decisions.
In the Raji B-cell malignancy background, MELK disruption holds particular significance for understanding aggressive lymphomas and leukemias, including Burkitt lymphoma and acute lymphoblastic leukemia. The EBV-positive environment introduces additional layers of deregulated signaling; MELK knockout cells allow researchers to dissect how this kinase cooperates with viral oncoproteins such as LMP1 and EBNA2, or with dysregulated MYC, to sustain high proliferation rates and evade apoptosis. Since Raji cells actively engage in antibody production and antigen presentation, the model also opens opportunities to explore potential crosstalk between MELK-dependent cell cycle control and immune effector functions, an area relevant to tumor-immune interactions.
Typical research applications span kinase inhibitor screening and drug sensitivity profiling, where this knockout model serves as an isogenic background to validate MELK-targeted compounds by comparing drug responses in wild-type versus MELK-disrupted cells. Cell cycle and apoptosis analyses are straightforward using flow cytometry-based propidium iodide staining or Annexin V assays, while phospho-signaling analysis via western blotting and RT-qPCR enables tracking of downstream targets like CDC25B and BCL2L12. Proliferation assays and functional genomics studies benefit from the polyclonal population??s stable growth characteristics, supporting large-scale loss-of-function screens. For further information or to request a quote, please contact Ascent Research.
